Your browser doesn't support javascript.
loading
Development of a Patient-Reported Outcomes Tool to Assess Pain and Discomfort in Autosomal Dominant Polycystic Kidney Disease.
Oberdhan, Dorothee; Cole, Jason C; Atkinson, Mark J; Krasa, Holly B; Davison, Sara N; Perrone, Ronald D.
Affiliation
  • Oberdhan D; Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, Maryland.
  • Cole JC; P3 Research Consulting, LLC, Torrance, California.
  • Atkinson MJ; COA Evidentiary Analytics, LLC, Powers, Oregon.
  • Krasa HB; Department of Family Medicine and Public Health, University of California San Diego, San Diego, California.
  • Davison SN; Blue Persimmon Group, LLC, Washington, DC.
  • Perrone RD; Department of Medicine, University of Alberta, Edmonton, Canada.
Clin J Am Soc Nephrol ; 18(2): 213-222, 2023 02 01.
Article in En | MEDLINE | ID: mdl-36754008
ABSTRACT

BACKGROUND:

Pain has been identified as a core outcome for individuals with autosomal dominant polycystic kidney disease (ADPKD), but no disease-specific pain assessment has been developed using current development methodology for patient-reported outcomes (PRO) instruments. We developed and validated an ADPKD-specific pain questionnaire the ADPKD Pain and Discomfort Scale (ADPKD-PDS).

METHODS:

Conceptual underpinnings were drawn from literature review, concept elicitation, expert consultation, and measurement performance. In the qualitative analysis phase, concepts were elicited from focus groups of adults with ADPKD, and the resulting draft instrument was refined using cognitive debriefing interviews with individuals with ADPKD. For quantitative analysis, adults with ADPKD completed the draft instrument and other PRO tools in an online survey, and a follow-up survey was conducted 3-4 weeks later. Survey responses were analyzed for item-level descriptive statistics, latent model fit statistics, item discrimination, item- and domain-level psychometric statistics, test-retest reliability, responsiveness to change, and convergent validity.

RESULTS:

In the qualitative phase, 46 focus groups were conducted in 18 countries with 293 participants. Focus groups described three conceptually distinct types of ADPKD-related pain and discomfort (dull kidney pain, sharp kidney pain, and fullness/discomfort). In the quantitative phase, 298 adults with ADPKD completed the online survey, and 108 participants completed the follow-up survey. After iterative refinement of the instrument, latent variable measurement models showed very good fit (comparative fit and nonnormed fit indices both 0.99), as did item- and domain-level psychometric characteristics. The final ADPKD-PDS contains 20 items assessing pain severity and interference with activities over a 7-day recall period.

CONCLUSIONS:

The ADPKD-PDS is the first validated tool for systematically assessing pain and discomfort in ADPKD.
Subject(s)

Full text: 1 Database: MEDLINE Main subject: Polycystic Kidney, Autosomal Dominant Type of study: Diagnostic_studies / Prognostic_studies / Qualitative_research Limits: Adult / Humans Language: En Year: 2023 Type: Article

Full text: 1 Database: MEDLINE Main subject: Polycystic Kidney, Autosomal Dominant Type of study: Diagnostic_studies / Prognostic_studies / Qualitative_research Limits: Adult / Humans Language: En Year: 2023 Type: Article